Published in final edited form as:

Neurobiol Aging. 2017 October ; 58: 240.e1–240.e3. doi:10.1016/j.neurobiolaging.2017.06.019.

Mutations in *TYROBP* are not a common cause of dementia in a Turkish cohort

Lee Darwent^{a,1}, Susana Carmona^{a,1}, Ebba Lohmann^{b,c}, Gamze Guven^d, Celia Kun-Rodrigues^a, Basar Bilgic^b, Hasmet Hanagasi^b, Hakan Gurvit^b, Nihan Erginel-Unaltuna^d, Meltem Pak^b, John Hardy^a, Andrew Singleton^e, Jose Brás^{a,f,g}, and Rita Guerreiro^{a,f,g,*}

^aDepartment of Molecular Neuroscience, Institute of Neurology, University College London, London, UK

^bBehavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

^cDepartment of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen and German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany

^dGenetics Department, Aziz Sancar Institute for Experimental Medicine, Istanbul University, Istanbul, Turkey

^eLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA

^fDepartment of Medical Sciences, Institute of Biomedicine—BiMED, University of Aveiro, Aveiro, Portugal

^gUK Dementia Research Institute at UCL (UK DRI), London, UK

Abstract

Mutations in *TYROBP* and *TREM2* have been shown to cause polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy. Recently, variants in *TREM2* were also associated with frontotemporal dementia and Alzheimer's disease. Given the functional proximity between these 2 genes, we investigated the genetic variation of *TYROBP* in a Turkish cohort of 103 dementia patients. No mutations or copy number variants predicted to be pathogenic were identified. These results indicate that mutations in *TYROBP* are not a common cause of dementia in this Turkish cohort.

*Corresponding author at: Department of Molecular Neuroscience, Institute of Neurology, University College London, Queen Square, London, UK. Tel.: +44 (0) 207 679 4256; fax: +44 (0) 203 448 4017. r.guerreiro@ucl.ac.uk, ritajoao@gmail.com (R. Guerreiro).

¹These authors contributed equally to this work.

Disclosure statement

The authors have no conflicts of interest to disclose.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.neurobiolaging.2017.06.019>.

Keywords

TYROBP, Dementia; Genetic variant; Turkish cohort; Whole-genome genotyping; Whole-exome sequencing

1. Introduction

TYRO protein tyrosine kinase binding protein (TYROBP, also known as DAP12) is a transmembrane signaling protein. In microglia, TYROBP binds to different receptors, including TREM2, SIRP β 1, and CR3 (Ma et al., 2015). The TYROBP-receptor complex activates microglia phagocytosis and inflammation response in the brain (Linnartz et al., 2010).

Biallelic mutations in *TYROBP* and *TREM2* have been described as causative of polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOS, also known as Nasu-Hakola disease; OMIM: 221770). The same type of mutations in *TREM2* were also found to cause frontotemporal dementia (FTD) without the typical bone phenotypes found in PLOS (Guerreiro et al., 2013a), and heterozygous rare variants have been shown to modulate the risk of Alzheimer's disease (Guerreiro et al., 2013b; Jonsson et al., 2013).

More recently, an enrichment of *TYROBP* rare variants was reported in patients with early-onset Alzheimer's disease (Pottier et al., 2016), and increased mRNA expression levels of *TYROBP* were found in the brain of LOAD patients (Zhang et al., 2013).

Given these recent results and the close functional interaction between TREM2 and TYROBP, we aimed to investigate the genetic variation of *TYROBP* in a cohort of Turkish dementia cases overlapping with the one where we previously identified 3 *TREM2* mutations as the cause of an atypical FTD phenotype (Guerreiro et al., 2013a).

2. Materials and methods

We analyzed a cohort of 103 Turkish dementia cases including patients with mild cognitive impairment (20 patients), Alzheimer's disease (AD; 50 patients), FTD (24 patients), and other forms of dementia (9 patients; Table S1). All cases were negative for pathogenic mutations in dementia genes (list of genes in Supplementary Material). Samples were whole-genome genotyped, and data were analyzed to identify large (>50 kb) copy number variants (CNVs) and large tracts of homozygosity (>1 Mb) within the *TYROBP* locus. Whole-exome sequencing (WES) was performed to retrieve variability in the coding and immediate intronic regions of *TYROBP* and Sanger sequencing was done in samples with no WES data and for exons with low coverage in WES. Details for the methods used are available in the Supplementary Data.

3. Results

No copy number variants or large tracts of homozygosity were identified at the *TYROBP* locus in the 103 samples studied. Similarly, the analysis of WES and Sanger sequencing data revealed no biallelic missense mutations or small insertions or deletions predicted to be

pathogenic. The low frequency, synonymous variant p.Gly41Gly (rs111477177) was identified in 4 patients. The missense variant p.Val55Leu (rs77782321) was found to always be associated with c.94+71T>C and c.*25A>C (Fig. 1, Table S2) and was identified in 3 patients with clinical diagnoses of AD, FTD, or mild cognitive impairment. These variants (p.Gly41Gly and p.Val55Leu) were detected in the heterozygous state in all samples and predicted as benign according to *in silico* analysis.

4. Discussion

TYROBP is a transmembrane adapter protein that couples with cell membrane receptors, including TREM2. Given the functional proximity of both genes, we have studied the possible involvement of genetic variability in *TYROBP* in dementia, by assessing a cohort of Turkish dementia cases. This is a genetically well-characterized cohort where we have previously identified *TREM2* biallelic mutations as the cause of an atypical FTD syndrome in 3 cases. This population has the ideal characteristics for such studies due to the high degree of consanguineous marriages and consequent high likelihood of autosomal recessive disorders.

No large structural variants or large regions of homozygosity were identified in the *TYROBP* locus. Three individuals were found to be carriers of the missense p.Val55Leu. This variant was previously found in a patient with early-onset Alzheimer's disease also carrying the p.Gly2Glu and to be absent in control population (Pottier et al., 2016). The global allelic frequency of p.Val55Leu in the general population is 0.015, being more frequent in the Asian population. This variant is classified as benign by different *in silico* prediction software of pathogenicity. These results indicate that *TYROBP* mutations are not a common cause of dementia in the Turkish population. TYROBP was shown to be a key regulator of microglia functions (Zhang et al., 2013) and has a number of loss of function variants that is lower than what is predicted as expected by ExAC (probability of loss of function intolerance of 0.49). These facts suggest that TYROBP may have a critical physiological role, and/or other biological functions that prevent a high rate of mutability. Given the low number of variants in the gene and the low frequency of minor alleles in the population, further studies including larger cohorts will be required to fully understand the involvement of this gene in dementia.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors thank all the patients and their families. Jose Bras and Rita Guerreiro's work is funded by Fellowships from the Alzheimer's Society. This work was partially funded by Alzheimer's Research UK, Alzheimer's Society, and an anonymous donor. Ebba Lohmann is supported by a grant from the Deutsche Forschungsgemeinschaft in Germany.

References

- Guerreiro RJ, Lohmann E, Brás JM, Gibbs JR, Rohrer JD, Gurunlian N, Dursun B, Bilgic B, Hanagasi H, Gurvit H, Emre M, Singleton A, Hardy J. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. *JAMA Neurol.* 2013a; 70:78–84. [PubMed: 23318515]
- Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J. Alzheimer Genetic Analysis Group. TREM2 variants in Alzheimer's disease. *N. Engl. J. Med.* 2013b; 368:117–127. [PubMed: 23150934]
- Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K. Variant of TREM2 associated with the risk of Alzheimer's disease. *N. Engl. J. Med.* 2013; 368:107–116. [PubMed: 23150908]
- Linnartz B, Wang Y, Neumann H. Microglial immunoreceptor tyrosine-based activation and inhibition motif signaling in neuroinflammation. *Int. J. Alzheimers Dis.* 2010; 2010
- Ma J, Jiang T, Tan L, Yu JT. TYROBP in Alzheimer's disease. *Mol. Neurobiol.* 2015; 51:820–826. [PubMed: 25052481]
- Pottier C, Ravenscroft TA, Brown PH, Finch NA, Baker M, Parsons M, Asmann YW, Ren Y, Christopher E, Levitch D, van Blitterswijk M, Cruchaga C, Campion D, Nicolas G, Richard AC, Guerreiro R, Bras JT, Zuchner S, Gonzalez MA, Bu G, Younkin S, Knopman DS, Josephs KA, Parisi JE, Petersen RC, Ertekin-Taner N, Graff-Radford NR, Boeve BF, Dickson DW, Rademakers R. TYROBP genetic variants in early-onset Alzheimer's disease. *Neurobiol. Aging.* 2016; 48:222.e9–222.e15.
- Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezhnikov AA, Zhang C, Xie T, Tran L, Dobrin R, Fluder E, Clurman B, Melquist S, Narayanan M, Suver C, Shah H, Mahajan M, Gillis T, Mysore J, MacDonald ME, Lamb JR, Bennett DA, Molony C, Stone DJ, Gudnason V, Myers AJ, Schadt EE, Neumann H, Zhu J, Emilsson V. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. *Cell.* 2013; 153:707–720. [PubMed: 23622250]

Fig. 1.

Schematic representation of TYROBP (NP_003323) with the previously identified mutations in PLOSL (top) and EOAD (bottom). PLOSL mutations were found in the homozygous or compound heterozygous states. Variants identified in EOAD were found in the heterozygous state. The variant p.Val55Leu found in this study is represented in bold. Abbreviations: EOAD, early-onset Alzheimer's disease; PLOSL, polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy.